Endocrinology

Ordering an obesity phenotype should be as simple and routine as ordering an HbA1c or a lipid panel, says obesity expert Andres Acosta, MD, PhD.

Mayo Clinic's Andres Acosta, MD, PhD, details the 4 biologic obesity phenotypes his team has identified and how their use can change weight loss outcomes.

Use of GLP-1 mimetics and SGLT-2 inhibitors for cardiorenal protection in T2D patients is backed by robust clinical trial evidence, says AACE President Sethu Reddy, MD.

AACE president Dr Sethu Reddy highlights evidence-based updates, including selection of diabetes medication based on comorbidities and new agents to treat DKD and elevated lipids.

Semaglutide yields "amazing" weight loss in adolescents, phenotype-tailored lifestyle approach leads to greater weight loss vs standard methods, and more.

In the SOLOIST-WHF trial, risk for HF readmission and CV death were reduced by more than 50% at 30- and 90-days after hospital discharge.

Empagliflozin achieved a decrease in risk of kidney disease progression of 28% vs placebo in the most diverse population of patients in an SGLT-2 inhibitor trial.

Reddy talks about the value of A1c vs results of an OGTT for T2D diagnosis, about glycemic targets and patient safety, hyperglycemia during pregnancy, and more in our interview.

ObesityWeek® 2022. Primary care clinicians report providing on average just 70% of a wide range of clinical weight management services, according to a new survey.

ObesityWeek® 2022. Coagonism of the glucagon and GLP-1 receptors appears to result in greater weight loss than GLP-1 receptor agonism alone, study suggests.

ObesityWeek 2022: Tirzepatide-induced weight reduction was associated with body composition improvements in adults with obesity/overweight, found analysis of SURMOUNT-1.

Your daily dose of clinical news you may have missed.

In patients with prediabetes and untreated type 2 diabetes, a reduced carbohydrate diet improved HbA1c and other metabolic markers vs a usual diet.

Your daily dose of clinical news you may have missed.

Your daily dose of clinical news from Patient Care Online.

CMHC 2022: A decrease in vitamin D levels is associated with increased cardiovascular risk in patients with type 2 diabetes, according to new study.

Analysis of national health data found that 16.5% of all adult insulin users skipped doses in the past year.

Weight loss of at least 5% to 10% for persons with T2D is realistic and essential, says Nisa Maruthur, MD, MHS, coauthor of the new ADA/EASD consensus report.

Nisa Maruthur, MD, MHS, a primary care physician and consensus report coauthor, discusses elements of the most effective care for patients with type 2 diabetes (T2D).

Novel NMDA receptor antagonist approved for the treatment of major depressive disorder, first topical PDE4i approved for plaque psoriasis, and more.

Hospital admissions among patients with T2D taking basal insulin only were reduced by 67% one year after beginning treatment with the CGM system.

Blood pressure-lowering therapy reduced the risk of major CV events in persons with and without type 2 diabetes, according to an individual participant-level data meta-analysis.

"Primary Viewpoints," a podcast from Patient Care Online, brings you an exclusive interview with Hiddo Heerspink, PhD, PharmD.

A new study found patients with T1D and T2D had a greater risk for stenotic lesions, whereas risk for valvular regurgitation was lower in those with T2D.

ADA 2022: Patients with T2D who received a treatment intervention powered by artificial intelligence achieved a remission rate of more than 80%.